Context
The optimal management of pregnancy and lactation-associated osteoporosis (PLO) has not been designated.
Objective
To systematically review the best available evidence regarding the effect of different therapeutic interventions on bone mineral density (BMD) and risk of fractures in these patients.
Data sources
A comprehensive search was conducted in PubMed/Scopus databases until December 20th, 2022. Data were expressed as weighted mean difference (WMD) with 95% confidence intervals (CI). I2index was employed for heterogeneity.
Study Selection
Studies conducted in women with PLO who received any anti-osteoporosis therapy were included. Studies including women with secondary causes of osteoporosis or with transient osteoporosis of the hip were excluded.
Data extraction
Data extraction was independently completed by two researchers.
Data synthesis
Sixty-six studies were included in the qualitative analysis (n=451; follow-up time range: 6-264 months; age range: 19-42 years).
The increase in lumbar spine (LS) BMD with calcium/vitamin D (CaD), bisphosphonates and teriparatide was 2.0-7.5%, 5.0-41.5% and 8.0-24.4% at 12 months and 11.0-12.2%, 10.2-171.9% and 24.1-32.9% at 24 months, respectively. Femoral neck (FN) BMD increased by 6.1% with CaD and by 0.7-18% and 8.4-18.6% with bisphosphonates and teriparatide (18-24 months), respectively.
Meta-analysis was performed only for two interventional studies. Teriparatide induced a greater increase in LS and FN BMD compared with CaD [WMD 11.5% (95% CI 4.9-18.0%, I2 50.9%) and 5.4% (95% CI 1.2-9.6%, I2 8.1%), respectively].
Conclusions
Due to high heterogeneity and lack of robust comparative data, no safe conclusions can be made regarding the optimal therapeutic intervention in women with PLO.